Last checked at 20 Jun 2016 14:24
ValiRx Plc
("ValiRx" or "the Company")
RESULT OF ANNUAL GENERAL MEETING
London, UK, 20th June 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, announces that at its Annual General Meeting ("AGM") held earlier today, Resolutions 1 to 5 were passed. Resolution 6, whilst supported by the majority of Shareholders, did not receive the necessary level of support to be passed at this time. A further announcement will follow in due course.
*** ENDS ***
For more information, please contact:
ValiRx plc | Tel: +44 (0) 20 3008 4416 www.valirx.com |
Dr Satu Vainikka, Chief Executive | Tel: +44 (0) 20 3008 4416 |
Tarquin Edwards, Head of Communications. | Tel: +44 (0) 7879 458 364 tarquin.edwards@valirx.com |
Mark Treharne, Corporate Development Manager | Tel: +44 (0) 7736 564 686 mark.treharne@valirx.com |
Cairn Financial Advisers LLP (Nominated Adviser) | Tel: +44 (0) 20 7148 7900 |
Liam Murray | |
Northland Capital Partners Limited (Joint Broker) | Tel: +44 (0) 203 861 6625 |
Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking) | |
Beaufort Securities Limited (Joint Broker) | Tel: +44 (0) 207 382 8300 |
Jon Belliss |